Manuel Palacios

Manuel Palacios

Auto-generated profile, based on publicly available information

Manuel Palacios

Centro de Investigación Biomédica en Red (CIBERER), ISCIII, Madrid, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JLJuan M Lozano-Gil
Juan M Lozano-Gil
LRLola Rodríguez-Ruiz
Lola Rodríguez-Ruiz
MPManuel Palacios
Manuel Palacios
JPJorge Peral
Jorge Peral
SNSusana Navarro
Susana Navarro
Victoriano MuleroVictoriano Mulero
Victoriano Mulero
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.